HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ryosuke Tsuchiya Kenji Suzuki Yukito Ichinose Yoh Watanabe Harubumi Kato Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsuchiya, R. Articles by Kato, H. Search for Related Content PubMed PubMed Citation Articles by Tsuchiya, R. Articles by Kato, H. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2005;129:977-983
© 2005 The American Association for Thoracic Surgery

General Thoracic Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)

^a Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo
^b Department of Thoracic Oncology of the National Kyushu Cancer Center, Kyushu
^c Department of Surgery of the University of Kanazawa, Kanazawa
^d Department of Surgery of the Habikino Hospital, Osaka
^e JCOG Data Center of the National Cancer Center, Tokyo
^f Department of Surgery of the Tokyo Medical College, Tokyo, Japan; and the Lung Cancer Surgical Study Group of Japan Clinical Oncology Group

Received for publication September 3, 2003; revisions received April 21, 2004; accepted for publication May 6, 2004.

^_* Address for reprints: Ryosuke Tsuchiya, MD, Thoracic Surgery Division, National Cancer Center Hospital, 1-1, Tsukiji 5 cho-me, Chuo-ku, Tokyo 104-0045 Japan (E-mail: rtsuchiy{at}ncc.go.jp).

OBJECTIVE: Indications for surgical intervention for very limited small cell lung cancer have not yet been determined. The objective of this study is to determine whether resection followed by cisplatin and etoposide is feasible.

METHODS: From September 1991 through December 1996, 62 patients with completely resected small cell lung cancer who were less than 76 years of age from 17 centers were entered in the trial. Of 62 patients, 61 were eligible, with a median follow-up of 65 months. Chemotherapy consisted of 4 cycles of cisplatin (100 mg/m², day 1) and etoposide (100 mg/m², days 1–3). There were 49 (80%) male patients, 44 with clinical stage I disease, 10 with stage II disease, and 6 with stage IIIa disease.

RESULTS: Forty-two (69%) patients received 4 cycles of cisplatin and etoposide. No treatment-associated mortality was noted. Median survival time was not reached in patients with pathologic stage I disease, was 449 days in patients with stage II disease, and was 712 days in patients with stage IIIa disease. Three-year survival was 61% overall, 68% in patients with clinical stage I disease, 56% in patients with stage II disease, and 13% in patients with stage IIIa disease (P = .02). Recurrence was noted in 26 (43%) patients overall. Local failure was noted in 6 (10%) patients. Locoregional recurrence tends to be found more frequently in patients with stage IIIA disease. Distant failure was found in 21 (34%) patients overall. Brain metastasis was found in 15% of the patients.

CONCLUSION: Major lung resection followed by postoperative cisplatin and etoposide is feasible, with a favorable survival profile. Because nodal metastasis appears to be a major prognostic factor, preoperative evaluation of nodal status remains a major concern.

This article has been cited by other articles:

				M. A. Socinski and J. A. Bogart Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145. [Abstract] [Full Text] [PDF]

				Y. Fujiwara, I. Sekine, K. Tsuta, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, K. Yamada, and T. Tamura Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung Jpn. J. Clin. Oncol., July 24, 2007; (2007) hym053v1. [Abstract] [Full Text] [PDF]